Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib, Pertuzumab, Trastuzumab, and Paclitaxel in Breast Cancer
NCT03101748Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2018
- Primary completion
- May 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of neratinib in breast cancer, inflammatory breast cancer (IBC), sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2018; status: terminated.
02
Drugs
neratinib
03
Conditions
breast cancerinflammatory breast cancer (IBC)
Beyond the preview
Go deeper on NCT03101748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03101748.